These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34708098)

  • 1. The Placebo-Controlled Effect of Percutaneous Coronary Intervention on Exercise Induced Changes in Anti-Malondialdehyde-LDL Antibody Levels in Stable Coronary Artery Disease: A Substudy of the ORBITA Trial.
    Hartley A; Shun-Shin M; Caga-Anan M; Rajkumar C; Nowbar AN; Foley M; Francis DP; Haskard DO; Khamis RY; Al-Lamee RK
    Front Cardiovasc Med; 2021; 8():757030. PubMed ID: 34708098
    [No Abstract]   [Full Text] [Related]  

  • 2. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Al-Lamee R; Thompson D; Dehbi HM; Sen S; Tang K; Davies J; Keeble T; Mielewczik M; Kaprielian R; Malik IS; Nijjer SS; Petraco R; Cook C; Ahmad Y; Howard J; Baker C; Sharp A; Gerber R; Talwar S; Assomull R; Mayet J; Wensel R; Collier D; Shun-Shin M; Thom SA; Davies JE; Francis DP;
    Lancet; 2018 Jan; 391(10115):31-40. PubMed ID: 29103656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease.
    Al-Lamee R; Howard JP; Shun-Shin MJ; Thompson D; Dehbi HM; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik IS; Cook C; Ahmad Y; Sharp ASP; Gerber R; Baker C; Kaprielian R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom SA; Davies JE; Francis DP
    Circulation; 2018 Oct; 138(17):1780-1792. PubMed ID: 29789302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial.
    Nowbar AN; Rajkumar C; Foley M; Ahmed-Jushuf F; Howard JP; Seligman H; Petraco R; Sen S; Nijjer SS; Shun-Shin MJ; Keeble TR; Sohaib A; Collier D; McVeigh P; Harrell FE; Francis DP; Al-Lamee RK
    EuroIntervention; 2022 Apr; 17(18):1490-1497. PubMed ID: 35156616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial.
    McCreanor V; Nowbar A; Rajkumar C; Barnett AG; Francis D; Graves N; Boden WE; Weintraub WS; Al-Lamee R; Parsonage WA
    BMJ Open; 2021 Feb; 11(2):e044054. PubMed ID: 33563623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Serum Malondialdehyde-Modified Low-Density Lipoprotein and Coronary Angiographic Progression After Drug-Eluting Stent Implantation in Patients With Stable Angina.
    Yokoi M; Ito T; Fujita H; Sugiura T; Seo Y; Ohte N
    Circ J; 2020 Sep; 84(10):1837-1845. PubMed ID: 32863287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiopulmonary exercise testing and efficacy of percutaneous coronary intervention: a substudy of the ORBITA trial.
    Ganesananthan S; Rajkumar CA; Foley M; Thompson D; Nowbar AN; Seligman H; Petraco R; Sen S; Nijjer S; Thom SA; Wensel R; Davies J; Francis D; Shun-Shin M; Howard J; Al-Lamee R
    Eur Heart J; 2022 Sep; 43(33):3132-3145. PubMed ID: 35639660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Amioka N; Miyoshi T; Otsuka H; Yamada D; Takaishi A; Ueeda M; Hirohata S; Ito H
    J Cardiol; 2019 Sep; 74(3):258-266. PubMed ID: 30898480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent.
    Ito T; Fujita H; Tani T; Ohte N
    Atherosclerosis; 2015 Apr; 239(2):311-7. PubMed ID: 25682029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of Life Assessment in Trials of Revascularization for Chronic Stable Angina: Insights from ORBITA and the Implications of Blinding.
    Nowbar AN; Francis DP; Al-Lamee RK
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):1011-1018. PubMed ID: 34417901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dobutamine Stress Echocardiography Ischemia as a Predictor of the Placebo-Controlled Efficacy of Percutaneous Coronary Intervention in Stable Coronary Artery Disease: The Stress Echocardiography-Stratified Analysis of ORBITA.
    Al-Lamee RK; Shun-Shin MJ; Howard JP; Nowbar AN; Rajkumar C; Thompson D; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik I; Bual N; Cook C; Ahmad Y; Seligman H; Sharp ASP; Gerber R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom S; Davies JE; Francis DP
    Circulation; 2019 Dec; 140(24):1971-1980. PubMed ID: 31707827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The challenges of a randomised placebo-controlled trial of CTO PCI vs. placebo with optimal medical therapy: The ORBITA-CTO pilot study design and protocol.
    Khan S; Fawaz S; Simpson R; Robertson C; Kelly P; Mohdnazri S; Tang K; Cook CM; Gallagher S; O'Kane P; Spratt J; Brilakis ES; Karamasis GV; Al-Lamee R; Keeble TR; Davies JR
    Front Cardiovasc Med; 2023; 10():1172763. PubMed ID: 37206100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina.
    Leibundgut G; Lee JH; Strauss BH; Segev A; Tsimikas S
    J Thromb Thrombolysis; 2016 May; 41(4):569-80. PubMed ID: 26964999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in serum malondialdehyde-modified low-density lipoprotein in patients with acute myocardial infarction and stable angina pectoris treated by coronary angioplasty].
    Araki T; Kanaya H; Shimizu M; Mabuchi H; Kitayama M; Kanemitsu S; Takekoshi N;
    J Cardiol; 2001 Aug; 38(2):55-60. PubMed ID: 11525110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention.
    Ishii H; Nishio M; Takahashi H; Aoyama T; Tanaka M; Toriyama T; Tamaki T; Yoshikawa D; Hayashi M; Amano T; Matsubara T; Murohara T
    Clin Ther; 2010 Dec; 32(14):2337-47. PubMed ID: 21353104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus.
    Kotani K; Tashiro J; Yamazaki K; Nakamura Y; Miyazaki A; Bujo H; Saito Y; Kanno T; Maekawa M
    Clin Chim Acta; 2015 Oct; 450():145-50. PubMed ID: 26265234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ORBITA: What Goes Around, Comes Around… Or Does It?
    Jackson M; Zaman A
    Interv Cardiol; 2018 Sep; 13(3):135-136. PubMed ID: 30443270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional Effect of Coronary High-Intensity Plaque on T1-Weighted Magnetic Resonance Imaging With Circulating Malondialdehyde-Modified Low-Density Lipoprotein on Cardiac Events.
    Hiraya D; Sato A; Hoshi T; Sakai S; Watabe H; Ieda M
    Circ J; 2021 Oct; 85(11):2032-2039. PubMed ID: 34275962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates of Elective Percutaneous Coronary Intervention in England and Wales: Impact of COURAGE and ORBITA Trials.
    Rashid M; Stevens C; Wijeysundera HC; Curzen N; Khoo CW; Mohamed MO; Aktaa S; Wu J; Ludman PF; Mamas MA
    J Am Heart Assoc; 2022 Sep; 11(18):e025426. PubMed ID: 36102261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.